GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapid Dose Therapeutics Corp (XCNQ:DOSE) » Definitions » Cyclically Adjusted Revenue per Share

Rapid Dose Therapeutics (XCNQ:DOSE) Cyclically Adjusted Revenue per Share : C$0.01 (As of Nov. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Rapid Dose Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Rapid Dose Therapeutics's adjusted revenue per share for the three months ended in Nov. 2024 was C$0.004. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is C$0.01 for the trailing ten years ended in Nov. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-05-25), Rapid Dose Therapeutics's current stock price is C$0.19. Rapid Dose Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Nov. 2024 was C$0.01. Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio of today is 19.00.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Rapid Dose Therapeutics was 66.00. The lowest was 4.60. And the median was 17.00.


Rapid Dose Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Rapid Dose Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Dose Therapeutics Cyclically Adjusted Revenue per Share Chart

Rapid Dose Therapeutics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 0.01 0.01 0.01

Rapid Dose Therapeutics Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Competitive Comparison of Rapid Dose Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio falls into.


;
;

Rapid Dose Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rapid Dose Therapeutics's adjusted Revenue per Share data for the three months ended in Nov. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Nov. 2024 (Change)*Current CPI (Nov. 2024)
=0.004/127.8378*127.8378
=0.004

Current CPI (Nov. 2024) = 127.8378.

Rapid Dose Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 99.473 0.000
201409 0.000 99.394 0.000
201412 0.000 98.367 0.000
201503 0.000 99.789 0.000
201506 0.000 100.500 0.000
201509 0.000 100.421 0.000
201512 0.000 99.947 0.000
201603 0.000 101.054 0.000
201606 0.000 102.002 0.000
201609 0.000 101.765 0.000
201612 0.000 101.449 0.000
201703 0.000 102.634 0.000
201706 0.000 103.029 0.000
201709 0.000 103.345 0.000
201712 0.000 103.345 0.000
201809 0.000 105.636 0.000
201902 0.000 106.268 0.000
201905 0.000 107.927 0.000
201908 0.012 108.085 0.014
201911 -0.012 107.769 -0.014
202002 0.001 108.559 0.001
202005 0.000 107.532 0.000
202008 0.000 108.243 0.000
202011 0.002 108.796 0.002
202102 0.008 109.745 0.009
202105 0.010 111.404 0.011
202108 0.004 112.668 0.005
202111 0.005 113.932 0.006
202202 0.001 115.986 0.001
202205 0.001 120.016 0.001
202208 0.001 120.569 0.001
202211 0.003 121.675 0.003
202302 0.002 122.070 0.002
202305 0.002 124.045 0.002
202308 0.003 125.389 0.003
202311 0.002 125.468 0.002
202402 0.002 125.468 0.002
202405 0.003 127.601 0.003
202408 0.004 127.838 0.004
202411 0.004 127.838 0.004

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Rapid Dose Therapeutics  (XCNQ:DOSE) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.19/0.01
=19.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Rapid Dose Therapeutics was 66.00. The lowest was 4.60. And the median was 17.00.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Rapid Dose Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Rapid Dose Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Rapid Dose Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
1121 Walkers Line, Unit 3, Burlington, ON, CAN, L7N 2G4
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
Executives
Mark Upsdell Director
Brian Howlett Director

Rapid Dose Therapeutics Headlines

No Headlines